Traws Pharma, Inc. (TRAW)
Nasdaq · Healthcare · Biotechnology
$0.536−5.72%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $8.2M
- 52-week range
- $0.43 – $3.27
- 52-week change
- −74.67%
- EPS (trailing)
- −$1.71
Fiscal year to Dec 2025
- Revenue
- $2.8M (+1134.51%)
- Net income
- $9.2M
- Operating margin
- −640.7%
- Diluted EPS
- $0.82
- Free cash flow
- −$20.8M
From the company’s annual report on SEC EDGAR.
About Traws Pharma, Inc.
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Headquarters: Newtown, United States · 4 employees · trawspharma.com